Renaly

Renaly is an Israel-based medtech joint venture formed in 2021 by Venus Medtech and Healium Medical to develop next-generation renal denervation systems for hypertension. The company is focused on minimally invasive, ultrasound-based renal artery denervation devices intended to treat uncontrolled and resistant hypertension. Its technology is described as a dual-mode ultrasound platform that combines real-time imaging with noncontact continuous ablation to improve procedural precision, safety, and predictability. Renaly appears to operate as a controlled subsidiary of Venus Medtech and is positioned within cardiovascular intervention rather than therapeutics. Publicly available information indicates the lead product was in animal studies/preclinical development at the latest disclosed update.